Vilnius-based biotech startup Biomatter, which creates new proteins for health and sustainable manufacturing applications, has secured €6.5 million to expand its platform and develop new-to-the-world enzymes. The investment came from Inventure, UVC Partners, Practica Capital, and Metaplanet.
- Founded in 2018 by Donatas Repečka, Laurynas Karpus, Rolandas Meškys, and Vykintas Jauniskis, Biomatter develops an intelligent architecture platform that aims to overcome limitations in current engineering methods and open new avenues for protein design and development.
- Biomatter's platform allows for the creation and customization of enzymes based on specific needs and applications. This technology helps protein engineers design new enzymes from scratch or modify existing ones, making tailored molecules for various industries, including chemical manufacturing, agriculture, food, and life sciences.
“Enzymes will play a paramount part in the future of bioeconomy – they are the enabling piece that ultimately allows us to create new molecules, cells, and organisms for the world. At Biomatter, we believe that the unlimited capacity to design new enzymes will help to build a better tomorrow for everyone,” co-founder and CEO of Biomatter, Laurynas Karpus, commented.
- Biomatter has alredy partnered with various firms in the industry, including Thermo Fisher Scientific, EnginZyme, ArticZyme Technologies, and BASF.
Details of the deal
- The recent funding round was led by Inventure, a Helsinki-based venture capital firm managing €377 million in assets, which supports startups across the Nordics and Baltics with seed and Series A investments, and UVC Partners, an early-stage venture capital firm based in Munich and Berlin that invests in tech startups, with investment amounts ranging from €500,000 to €10 million.
“The application of AI in protein design will be transformational, addressing major current design limitations. Early results from projects with global companies show that Biomatter’s technology is dramatically accelerating innovation in this transformative field, reshaping the implementation of enzymes in incumbent and new structures. The team is rapidly expanding its platform to meet high customer demand," Investment Manager at Inventure, Kevin Lösch, stated.
- The investment round also included participation from existing investors Practica Capital and Metaplanet, along with business angels and industry experts.
- With the fresh capital raised, Biomatter plans to further expand the unique capabilities of its platform and create new-to-the-world enzymes.
